Abstract

The overall goal of this Core is to link the Atlanta HIV/AIDS clinical investigators into a network that will support research in the behavioral, therapeutic, virologic, immunologic, and pharmacologic aspects of HIV/AIDS. The Atlanta CFAR Clinical Core will provide well characterized clinical specimens to Atlanta/Emory CFAR investigators for clinical, behavioral, virologic, immunologic, and pharmacologic studies. The core will consist of 1) a database of 400 patients who volunteer to participate in the Core; 2) a repository of stored specimens from selected individuals in the database with specific characteristics; 3) capability of located individuals to provide specific specimens upon request and delivering those specimens to the requesting investigator. The Clinical Core will be located at four sites: the Ponce de Leon Center, the AIDS Research Consortium of Atlanta, the Crawford Long Hospital of Emory University, and the Atlanta VAMC Center for Excellence in AIDS Care. HIV-infected volunteers will be recruited, evaluated, and enrolled into the cohort at all four sites. At entry a demographic record will be established for each patient; these records will be updated every three months. From these 400 patients, a subgroup of 200 patients will be selected and asked to contribute serum and peripheral blood mononuclear cells to a specimen repository every three months.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
1P30DA012121-01
Application #
6104207
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322

  Publications

Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Thomas, Ajit G; Bodner, Amos; Ghadge, Ghanashyam et al. (2009) GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. J Neurovirol 15:449-57
Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory et al. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:1109-18
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41
Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095-106
Sadagopal, Shanmugalakshmi; Amara, Rama Rao; Kannanganat, Sunil et al. (2008) Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 82:4149-53
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67

Showing the most recent 10 out of 42 publications